• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines.

作者信息

Liu Xin, Wang Xiu-Jie

机构信息

Key Laboratory of Genetic Network Biology, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing, 100101, China.

Key Laboratory of Genetic Network Biology, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing, 100101, China; University of Chinese Academy of Sciences, Beijing, 100049, China; Innovation Academy for Seed Design, Chinese Academy of Sciences, Beijing, 100101, China.

出版信息

J Genet Genomics. 2020 Feb 20;47(2):119-121. doi: 10.1016/j.jgg.2020.02.001. Epub 2020 Feb 13.

DOI:10.1016/j.jgg.2020.02.001
PMID:32173287
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7128649/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4ac/7128649/0c26a0b576da/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4ac/7128649/0c26a0b576da/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4ac/7128649/0c26a0b576da/gr1_lrg.jpg

相似文献

1
Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines.来自临床批准药物的针对2019新型冠状病毒M蛋白酶的潜在抑制剂。
J Genet Genomics. 2020 Feb 20;47(2):119-121. doi: 10.1016/j.jgg.2020.02.001. Epub 2020 Feb 13.
2
[SARS-CoV-2 protease: an excellent target to develop drugs against COVID-19].[严重急性呼吸综合征冠状病毒2蛋白酶：开发抗2019冠状病毒病药物的理想靶点]
Med Sci (Paris). 2020 Jun-Jul;36(6-7):555-558. doi: 10.1051/medsci/2020106. Epub 2020 Jun 19.
3
Paromomycin: A potential dual targeted drug effectively inhibits both spike (S1) and main protease of COVID-19.巴龙霉素：一种潜在的双靶点药物，可有效抑制新冠病毒的刺突蛋白（S1）和主要蛋白酶。
Int J Infect Dis. 2020 Sep;98:166-175. doi: 10.1016/j.ijid.2020.06.063. Epub 2020 Jun 21.
4
In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection.计算机模拟揭示 SARS-CoV-2 主要蛋白酶，提示 NADH 内源性防御在控制大流行冠状病毒感染中的作用。
Viruses. 2020 Jul 26;12(8):805. doi: 10.3390/v12080805.
5
Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model.将临床批准的药物重新用于治疗 2019 年新型冠状病毒相关冠状病毒模型中的 2019 年冠状病毒病。
Chin Med J (Engl). 2020 May 5;133(9):1051-1056. doi: 10.1097/CM9.0000000000000797.
6
In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus.新型 SARS-CoV-2 病毒主要蛋白酶的批准蛋白酶抑制剂的有效性的计算机评估。
Molecules. 2020 May 29;25(11):2529. doi: 10.3390/molecules25112529.
7
Repurposing drugs against the main protease of SARS-CoV-2: mechanism-based insights supported by available laboratory and clinical data.重新利用药物对抗 SARS-CoV-2 的主蛋白酶：基于机制的见解，得到了现有实验室和临床数据的支持。
Mol Omics. 2020 Oct 1;16(5):474-491. doi: 10.1039/d0mo00057d. Epub 2020 Jul 22.
8
3CL inhibitors as a potential therapeutic option for COVID-19: Available evidence and ongoing clinical trials.3CL抑制剂作为COVID-19的一种潜在治疗选择：现有证据及正在进行的临床试验
Pharmacol Res. 2020 Jun;156:104779. doi: 10.1016/j.phrs.2020.104779. Epub 2020 Apr 2.
9
Macrolide treatment for COVID-19: Will this be the way forward?大环内酯类药物治疗 COVID-19：这将是未来的方向吗？
Biosci Trends. 2020 May 21;14(2):159-160. doi: 10.5582/bst.2020.03058. Epub 2020 Apr 5.
10
Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M enzyme through in silico approach.通过计算机模拟方法揭示抗 SARS-CoV-2 M 酶的具有抗病毒作用的植物化学成分
Life Sci. 2020 Aug 15;255:117831. doi: 10.1016/j.lfs.2020.117831. Epub 2020 May 22.

引用本文的文献

1
Development and validation of a LC-MS/MS method for the simultaneous determination of simnotrelvir and ritonavir in human serum and bronchoalveolar lavage fluid.用于同时测定人血清和支气管肺泡灌洗液中西莫瑞韦和利托那韦的液相色谱-串联质谱法的开发与验证。
BMC Chem. 2025 Jul 2;19(1):180. doi: 10.1186/s13065-025-01534-x.
2
Evolution of Antiviral Drug Resistance in SARS-CoV-2.新型冠状病毒（SARS-CoV-2）中抗病毒药物耐药性的演变
Viruses. 2025 May 18;17(5):722. doi: 10.3390/v17050722.
3
Navigating the COVID-19 Therapeutic Landscape: Unveiling Novel Perspectives on FDA-Approved Medications, Vaccination Targets, and Emerging Novel Strategies.

本文引用的文献

1
A Novel Coronavirus from Patients with Pneumonia in China, 2019.2019 年中国肺炎患者中的一种新型冠状病毒。
N Engl J Med. 2020 Feb 20;382(8):727-733. doi: 10.1056/NEJMoa2001017. Epub 2020 Jan 24.
2
The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China.新型冠状病毒持续的2019 - nCoV疫情对全球健康构成威胁——中国武汉最新的2019新型冠状病毒爆发。
Int J Infect Dis. 2020 Feb;91:264-266. doi: 10.1016/j.ijid.2020.01.009. Epub 2020 Jan 14.
3
Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle.
探索新冠病毒治疗领域：揭示关于美国食品药品监督管理局批准药物、疫苗接种目标及新兴策略的新观点
Molecules. 2024 Nov 25;29(23):5564. doi: 10.3390/molecules29235564.
4
Garlic bioactive substances and their therapeutic applications for improving human health: a comprehensive review.大蒜生物活性物质及其改善人类健康的治疗应用：全面综述。
Front Immunol. 2024 Jun 10;15:1277074. doi: 10.3389/fimmu.2024.1277074. eCollection 2024.
5
Parameter identifiability of a within-host SARS-CoV-2 epidemic model.宿主内新型冠状病毒2型（SARS-CoV-2）流行模型的参数可识别性
Infect Dis Model. 2024 May 14;9(3):975-994. doi: 10.1016/j.idm.2024.05.004. eCollection 2024 Sep.
6
The Inhibitory Effects of the Herbals Secondary Metabolites (7α-acetoxyroyleanone, Curzerene, Incensole, Harmaline, and Cannabidiol) on COVID-19: A Molecular Docking Study.草药次生代谢产物（7α-乙酰氧基罗勒烯酮、莪术烯、菖蒲烯、哈尔明碱和大麻二酚）对 COVID-19 的抑制作用：分子对接研究。
Recent Pat Biotechnol. 2024;18(4):316-331. doi: 10.2174/0118722083246773231108045238.
7
SARS-CoV-2 outbreak: role of viral proteins and genomic diversity in virus infection and COVID-19 progression.SARS-CoV-2 爆发：病毒蛋白和基因组多样性在病毒感染和 COVID-19 进展中的作用。
Virol J. 2024 Mar 27;21(1):75. doi: 10.1186/s12985-024-02342-w.
8
Non-alcoholic fatty liver disease (NAFLD) and COVID-19 outcomes: A systematic review, meta-analysis, and meta-regression.非酒精性脂肪性肝病（NAFLD）与2019冠状病毒病的转归：一项系统评价、荟萃分析和荟萃回归分析
Narra J. 2023 Apr;3(1):e102. doi: 10.52225/narra.v3i1.102. Epub 2023 Apr 19.
9
A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19.关于COVID-19的药物制剂、免疫疗法和支持性疗法的全面综述。
Narra J. 2022 Dec;2(3):e92. doi: 10.52225/narra.v2i3.92. Epub 2022 Dec 8.
10
anti-viral assessment of phytoconstituents in a traditional (Siddha Medicine) polyherbal formulation - Targeting Mpro and pan-coronavirus post-fusion Spike protein.一种传统（悉达医学）多草药配方中植物成分的抗病毒评估——以M蛋白酶和泛冠状病毒融合后刺突蛋白为靶点
J Tradit Complement Med. 2023 Jul 13;14(1):55-69. doi: 10.1016/j.jtcme.2023.07.004. eCollection 2024 Jan.
中国武汉不明原因肺炎疫情：谜团与奇迹
J Med Virol. 2020 Apr;92(4):401-402. doi: 10.1002/jmv.25678. Epub 2020 Feb 12.
4
Coronavirus envelope protein: current knowledge.冠状病毒包膜蛋白：当前的认识。
Virol J. 2019 May 27;16(1):69. doi: 10.1186/s12985-019-1182-0.
5
Origin and evolution of pathogenic coronaviruses.致病冠状病毒的起源与演化。
Nat Rev Microbiol. 2019 Mar;17(3):181-192. doi: 10.1038/s41579-018-0118-9.
6
Molecular dynamic simulations analysis of ritonavir and lopinavir as SARS-CoV 3CL(pro) inhibitors.利托那韦和洛匹那韦作为严重急性呼吸综合征冠状病毒3CL（蛋白酶）抑制剂的分子动力学模拟分析
J Theor Biol. 2008 Oct 21;254(4):861-7. doi: 10.1016/j.jtbi.2008.07.030. Epub 2008 Jul 29.
7
Structures of two coronavirus main proteases: implications for substrate binding and antiviral drug design.两种冠状病毒主要蛋白酶的结构：对底物结合及抗病毒药物设计的启示
J Virol. 2008 Mar;82(5):2515-27. doi: 10.1128/JVI.02114-07. Epub 2007 Dec 19.
8
Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs.冠状病毒主要蛋白酶（3CLpro）结构：抗非典药物设计的基础。
Science. 2003 Jun 13;300(5626):1763-7. doi: 10.1126/science.1085658. Epub 2003 May 13.
9
Cysteine proteases of positive strand RNA viruses and chymotrypsin-like serine proteases. A distinct protein superfamily with a common structural fold.正链RNA病毒的半胱氨酸蛋白酶和类胰凝乳蛋白酶样丝氨酸蛋白酶。一个具有共同结构折叠的独特蛋白质超家族。
FEBS Lett. 1989 Jan 30;243(2):103-14. doi: 10.1016/0014-5793(89)80109-7.